These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9572231)

  • 1. Chemotherapy resistance in ovarian cancer: new molecular perspectives.
    Coukos G; Rubin SC
    Obstet Gynecol; 1998 May; 91(5 Pt 1):783-92. PubMed ID: 9572231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemoresistance in ovarian cancer. State of the art and future prospects].
    Katsaros D; Fracchioli S; Arese P; Enria R; Cassinelli P; Mingrone K; Piccinno R; Rigault de la Longrais IA; Massobrio M
    Minerva Ginecol; 1999 Dec; 51(12):483-99. PubMed ID: 10767997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 gene status and chemosensitivity in ovarian cancer.
    Kigawa J; Sato S; Shimada M; Takahashi M; Itamochi H; Kanamori Y; Terakawa N
    Hum Cell; 2001 Sep; 14(3):165-71. PubMed ID: 11774736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microarray analysis revealed dysregulation of multiple genes associated with chemoresistance to As(2)O(3) and increased tumor aggressiveness in a newly established arsenic-resistant ovarian cancer cell line, OVCAR-3/AsR.
    Ong PS; Chan SY; Ho PC
    Eur J Pharm Sci; 2012 Feb; 45(3):367-78. PubMed ID: 22178533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
    Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
    Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control.
    Poulain L; Lincet H; Duigou F; Deslandes E; Sichel F; Gauduchon P; Staedel C
    Int J Cancer; 1998 Nov; 78(4):454-63. PubMed ID: 9797134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance in ovarian cancer: from the laboratory to the clinic.
    Sood AK; Buller RE
    Obstet Gynecol; 1998 Aug; 92(2):312-9. PubMed ID: 9699774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line.
    Çoban HŞ; Çil N; Önder E; Abban Mete G
    Mol Biol Rep; 2024 Apr; 51(1):485. PubMed ID: 38578399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
    Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
    Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.
    Metzinger DS; Taylor DD; Gercel-Taylor C
    Cancer Lett; 2006 May; 236(2):302-8. PubMed ID: 15990222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells.
    Takahashi M; Kigawa J; Minagawa Y; Itamochi H; Shimada M; Kamazawa S; Sato S; Akeshima R; Terakawa N
    Eur J Cancer; 2000 Sep; 36(14):1863-8. PubMed ID: 10974635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
    Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
    Li L; Luan Y; Wang G; Tang B; Li D; Zhang W; Li X; Zhao J; Ding H; Reed E; Li QQ
    Int J Mol Med; 2004 Aug; 14(2):257-64. PubMed ID: 15254775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids.
    L'Espérance S; Bachvarova M; Tetu B; Mes-Masson AM; Bachvarov D
    BMC Genomics; 2008 Feb; 9():99. PubMed ID: 18302766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.